[HTML][HTML] Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
JN Cormier, ML Salgaller, T Prevette… - The cancer journal …, 1997 - ncbi.nlm.nih.gov
JN Cormier, ML Salgaller, T Prevette, KC Barracchini, L Rivoltini, NP Restifo, SA Rosenberg…
The cancer journal from Scientific American, 1997•ncbi.nlm.nih.govPURPOSE In this study, we tested the effectiveness of a melanoma-associated antigen–
derived peptide, MART-1 27–35, in eliciting cellular immune responses in vivo in the context
of a phase I active immunization protocol. This peptide (AAGIGILTV) corresponds to
residues 27–35 from the nonmutated melanoma-associated antigen MART-1/Melan A and is
recognized by most melanoma-specific, HLA-A* 0201–restricted, tumor-infiltrating
lymphocytes. To test the in vivo induction of cytotoxic T lymphocyte (CTL) sensitization, we …
derived peptide, MART-1 27–35, in eliciting cellular immune responses in vivo in the context
of a phase I active immunization protocol. This peptide (AAGIGILTV) corresponds to
residues 27–35 from the nonmutated melanoma-associated antigen MART-1/Melan A and is
recognized by most melanoma-specific, HLA-A* 0201–restricted, tumor-infiltrating
lymphocytes. To test the in vivo induction of cytotoxic T lymphocyte (CTL) sensitization, we …
Abstract
PURPOSE
In this study, we tested the effectiveness of a melanoma-associated antigen–derived peptide, MART-1 27–35, in eliciting cellular immune responses in vivo in the context of a phase I active immunization protocol. This peptide (AAGIGILTV) corresponds to residues 27–35 from the nonmutated melanoma-associated antigen MART-1/Melan A and is recognized by most melanoma-specific, HLA-A* 0201–restricted, tumor-infiltrating lymphocytes. To test the in vivo induction of cytotoxic T lymphocyte (CTL) sensitization, we compared CTL reactivity in vitro from peripheral blood mono-nuclear cell (PBMC) pools obtained before and after vaccination.
ncbi.nlm.nih.gov